Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics Inc. (KTRA) news has centered on the issuer's biotechnology and immuno-oncology disclosure stream as recent records identify the company as TuHURA Biosciences, Inc. TuHURA is a Phase 3 immuno-oncology company developing therapeutics intended to overcome resistance to cancer immunotherapy.
Recurring developments include clinical-development leadership and strategy for the VISTA-inhibiting antibody TBS-2025 in blood-related cancers, innate immune agonist product candidates, Delta Opioid Receptor technology, antibody-drug conjugate work targeting Myeloid Derived Suppressor Cells, and updates on capital structure, material agreements, shareholder voting, governance, operating results, and risk factors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.